NextCure Bets Big on Cancer Drug SIM0505 Amidst Tightening Finances

BELTSVILLE, MD – March 05, 2026 – Clinical-stage biotech firm NextCure, Inc. has charted an ambitious course for 2026, pinning its hopes on a new generation of cancer therapies known as antibody-drug conjugates (ADCs). In a recent business update, the company detailed plans to accelerate the development of its lead candidate, SIM0505, for hard-to-treat cancers, even as its financial results reveal a shrinking cash reserve and a high-stakes race against time.

The company announced that crucial data from its Phase 1 trial of SIM0505 is expected in the second quarter of 2026, a milestone that could define its future. This comes as NextCure reported a net loss of $55.8 million for 2025 and a cash position of $41.8 million, highlighting the immense financial pressure inherent in late-stage drug development.

The ADC Gambit: SIM0505 Takes Center Stage

NextCure is staking its future on the promise of ADCs, which are designed to act like guided missiles, delivering potent chemotherapy payloads directly to cancer cells while sparing healthy tissue. The company's strategy hinges on two key programs: LNCB74 and, most critically, SIM0505, an ADC acquired in June 2025 from Simcere Zaiming Pharmaceutical.

SIM0505 targets cadherin-6 (CDH6), a protein overexpressed in several cancers, including ovarian and renal cancers, but found in limited quantities in healthy tissues. It carries a proprietary topoisomerase 1 inhibitor (TOPOi) payload designed for broad anti-tumor activity and rapid clearance from the body, which could lead to a better safety profile.

“2026 is on track to be transformational for NextCure, as we set the stage to present clinical dose escalation data from the Phase 1 trial for SIM0505,” said Michael Richman, President and CEO of NextCure, in the company's press release.

To capitalize on the drug's potential, NextCure is moving aggressively. The company plans to initiate a dose optimization study for SIM0505 in the second quarter of 2026, with a sharp focus on platinum-resistant ovarian cancer (PROC), a notoriously difficult-to-treat disease. Furthermore, NextCure intends to double its U.S. clinical trial sites and expand into Canada and Europe in the second half of the year to accelerate patient enrollment and data collection. This rapid expansion reflects a sense of urgency and confidence in the asset, which was already in clinical trials in China when NextCure licensed the ex-China rights.

A Crowded and Competitive Field

While NextCure is optimistic, it is entering a fiercely competitive arena. The therapeutic targets CDH6 and B7-H4 (the target of its other ADC, LNCB74) have attracted significant attention from major pharmaceutical players, all vying to develop the next blockbuster cancer drug.

For SIM0505, the primary competition comes from giants like Daiichi Sankyo and Merck, whose CDH6-targeting ADC, raludotatug deruxtecan (R-DXd), has already set a high bar. In a recent trial, R-DXd demonstrated an impressive 50.5% overall response rate in platinum-resistant ovarian cancer patients. Another competitor, OnCusp Therapeutics, received FDA Fast Track Designation for its CDH6 candidate, CUSP06.

NextCure is banking on SIM0505's potential differentiating factors. The company believes its candidate's proprietary payload and unique binding mechanism could result in superior efficacy or, crucially, an improved safety profile. The history of ADCs is littered with candidates that failed due to toxicity, including a previous CDH6-targeting drug, HKT288, that was halted due to neurotoxicity. Avoiding such pitfalls will be critical for SIM0505's success.

The landscape for its B7-H4 targeted ADC, LNCB74, is similarly crowded, with companies like Mersana Therapeutics and AstraZeneca reporting promising early data for their own candidates. NextCure plans to provide an update on its LNCB74 Phase 1 trial in the second half of 2026.

Targeting a Desperate Need in Ovarian Cancer

The intense focus on SIM0505 is driven by the profound unmet need in platinum-resistant ovarian cancer. For women with this diagnosis, the prognosis is grim. Once their cancer stops responding to standard platinum-based chemotherapy, effective treatment options are scarce, and median progression-free survival is a mere three to seven months.

The development of a new, effective therapy could be a game-changer for thousands of patients. By prioritizing PROC in its upcoming dose optimization study and expanding trial access globally, NextCure is positioning SIM0505 as a potential new hope in a field desperate for breakthroughs. The success of a novel therapy in this space would not only represent a significant clinical advance but also a substantial commercial opportunity.

The recent FDA approval of a new PD-1 inhibitor-based combination therapy for PROC demonstrates that progress is possible, but it also underscores the continuous need for more effective and durable treatments, a role that a well-tolerated and potent ADC like SIM0505 could potentially fill.

The Financial Tightrope

Underpinning this ambitious clinical strategy is a precarious financial reality. NextCure's 2025 financial report paints a picture of a company investing heavily in its future. Research and development expenses swelled to $44.9 million, largely driven by $18.5 million in license fees and milestone payments for SIM0505.

With $41.8 million in cash, cash equivalents, and marketable securities as of December 31, 2025, the company's financial runway is finite. NextCure projects these funds are sufficient to last into the first half of 2027, just long enough to obtain the crucial proof-of-concept data for SIM0505. This timeline leaves little room for error.

The upcoming Q2 2026 data readout is therefore a pivotal, make-or-break moment. Positive results would not only validate the company's nine-figure investment in SIM0505 but would also be essential for attracting the additional capital needed to fund later-stage trials and future operations. Disappointing data, on the other hand, could place the company in a difficult position. For NextCure, the path forward is a high-wire act, balancing groundbreaking science against the relentless ticking of the financial clock.